Non-Alcoholic Fatty Liver Disease Market, By Drug Class (THR- Agonists, GLP-1 Receptor Agonists, Antifibrotic Agents, FXR Agonists, Lipid-Lowering Agents, Thiazolidinediones, Antioxidants and Others), By Route of Administration, By Distribution, By Age Group, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5916
|
Published Date
August 2026
|
Pages
345
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Non-Alcoholic Fatty Liver Disease Market size was valued at US$ 3,405.2 Million in 2025, expanding at a CAGR of 16.3% from 2026 to 2033.
Non-alcoholic fatty liver disease (NAFLD) encompasses pharmaceuticals for the treatment of pathological fat accumulation, inflammation, and metabolic dysfunction, as well as therapies for liver fibrosis, including antioxidants, lipid-lowering agents, thiazolidinediones, FXR agonists, biguanides, and antifibrotic agents. Most drugs are administered orally, and there is a need for injectable therapies, including incretin-based and combination approaches.
The ideal approach is to stratify patients according to the stage of fibrosis and the associated metabolic disorders. In addition, the choice of therapy is based on biopsy-proven or non-invasive assessment of fibrosis progression, with an emphasis on the need for evidence of disease modification rather than only fat content reduction. According to the FDA, MASLD affects about 6% of U.S. adults, determining the need for the market to shift to a more individualized approach to treating patients with appropriate therapies.
Non-Alcoholic Fatty Liver Disease Market- Market Dynamics
Fibrosis Modification Moves Treatment Beyond Metabolic Risk Control
The current trend in clinical management is shifting toward the treatment of liver damage, not only weight loss or related conditions such as diabetes or dyslipidemia. The regulatory environment now focuses on trials targeting the resolution of fibrosis and steatohepatitis, which is an important differentiator for commercial success in the market for disease-modifying agents, increasing the relevance of specialist prescribers. Additionally, a higher level of evidence is required since the developer should provide either histological or validated non-invasive improvement, and long-term safety should be demonstrated. The FDA approved semaglutide for the treatment of MASLD in August 2025, as among the participants who received the drug, there was a resolution of MASLD without progression of fibrosis noted in 63%. The findings significantly impacted the subsequent wave of clinical trials and competition in the fibrosis market in the studied population.
Non-Alcoholic Fatty Liver Disease Market- Segmentation Analysis:
The Global Non-Alcoholic Fatty Liver Disease Market is segmented on the basis of Drug Class, Route of Administration, Distribution, Age Group, and Region.
Within the given drug-class segmentation, treatment options for fibrosis possess the most promising strategic positioning, of which disease modification emerged as the clearly stated unmet medical need. Therefore, therapies that have been proven to reduce progression by targeting the specific histological stages of the disease possess the biggest differential potential. Meanwhile, antioxidants, lipid-lowering agents, TZDs, and biguanides have a more limited scope due to their target indications, which are closely linked to addressing oxidative stress rather than disease modification. Although FXR agonists also affect liver fibrosis, their development has been limited due to recent regulatory concerns. Fibrosis-targeted treatment modalities were established due to the large and positive readout for the concept following the Rezdiffra study, which enrolled 917 patients with F2 or F3 and confirmed efficacy. Evidence from clinical trials plays the biggest role in shaping the generic positioning and specialist perceptions across regions.
Regarding the route of administration, oral is clearly superior due to the convenience of the dosing schedule, as well as overall simpler compliance compared to regular injections. Rezdiffra is taken once per day, which further highlights the potential for once-daily treatment across the fibrosis indications. Parenteral approaches are suitable for achieving greater exposure and utilizing the incretin effect, but they involve additional administration steps. The split in the route of administration is being challenged due to the launch of GLP-1 modulators, which possess disease-modifying potential. Within the indication, semaglutide\'s 240-week trial to demonstrate clinical benefit beyond histological improvement now needs to be approved by the FDA in 2025. Orally administered therapy will maintain the convenience differential over parenteral treatments, but the latter can leverage disease modification to increase the positioning.
Non-Alcoholic Fatty Liver Disease Market- Geographical Insights
A mature pharmaceutical market, hepatology expertise, and regulatory activity make North America the key commercial reference center for NAFLD therapies. The United States affords a combination of specialist input and metabolic care infrastructure, facilitating the arrival of liver-specific therapeutics within an established care pathway. In addition, the FDA approval of semaglutide for MASLD in the United States in 2025 provides both therapy options for the U.S. market and a direct comparison for other fibrosis-targeting agents. Fibrosis is a prevalent condition within the United States, with the FDA estimating that 14.9 million Americans have MASLD. North America is likely to remain the region of key influence for product launches, specialty uptake, and commercial success.
Europe is emerging as an alternative regulatory and clinical-development hub to the United States, both for the purposes of securing approvals and building clinical evidence. The EMA granted conditional approval to Rezdiffra in June 2025, with marketing authorization granted by the European Commission in August of the same year. It is the first MASLD therapy available in Europe, with positive data from its pivotal trial informing the regulatory decision. Within the trial, treatment of patients with Rezdiffra at 100 mg demonstrated improvements in fibrosis for 29% of patients with no worsening of MASLD in the treatment group, although longer-term evidence was requested by the EMA during the approval process. As such, Europe represents a region of significant commercial and clinical value, although variations in health technology assessment between countries will dictate the relative success of different therapies.
Non-Alcoholic Fatty Liver Disease Market- Competitive Landscape:
Competition is now focused on greater proof of fibrosis improvement, metabolic benefit, route of administration convenience, and the capacity to target a substantial number of specialists compared to the legacy management of symptoms. Madrigal\'s resmetirom created a precedent for an oral and liver-directed approach, while Novo Nordisk\'s semaglutide\'s MASLD indication made the company\'s injectable platform more attractive. Development is also concentrated on obesity, diabetes, and liver disease mechanisms, allowing the companies to capitalize on infrastructure and physician relationships. Novo Nordisk employs 69,505 workers globally as of 2025, exemplifying the investment required to navigate the development, manufacturing, and regulatory approval processes across multiple regions. The competitive position within the industry is now based on metabolic disease platforms, established liver endpoints, and commercial reach.
Recent Developments:
- In August 2025, Novo Nordisk\'s Wegovy (semaglutide) received FDA approval for the treatment of noncirrhotic MASH with moderate-to-advanced fibrosis, thereby expanding its therapeutic area to include liver disease and competing with resmetirom in the fibrosis-focused MASH treatment landscape.
- In August 2025, the European Commission granted conditional marketing authorization to Madrigal Pharmaceuticals for Rezdiffra (resmetirom) for the treatment of noncirrhotic MASH and moderate-to-advanced fibrosis in adults, thereby bringing its liver-directed drug therapy to the European Union.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Madrigal Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company
- Hoffmann-La Roche Ltd. / 89bio
- Gilead Sciences, Inc.
- AbbVie Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Inventiva S.A.
- AstraZeneca plc
- GSK plc
- Viking Therapeutics, Inc.
- Altimmune, Inc.
- Sagimet Biosciences Inc.
- Terns Pharmaceuticals, Inc.
- Galectin Therapeutics Inc.
- Galmed Pharmaceuticals Ltd.
- NGM Biopharmaceuticals, Inc.
- Bristol Myers Squibb
- Zydus Lifesciences Ltd.
- Others
GLOBALNON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- THR-β Agonists
- GLP-1 Receptor Agonists
- Antifibrotic Agents
- FXR Agonists
- Lipid-Lowering Agents
- Thiazolidinediones
- Antioxidants
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Parenteral
- Oral
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033
- Geriatric
- Adults
- Pediatric
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Non-Alcoholic Fatty Liver Disease Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.2. Competitive Insights
3. Non-Alcoholic Fatty Liver Disease Key Market Trends
3.1. Non-Alcoholic Fatty Liver Disease Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Non-Alcoholic Fatty Liver Disease Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Non-Alcoholic Fatty Liver Disease Market Opportunities
3.4. Non-Alcoholic Fatty Liver Disease Market Future Trends
4. Non-Alcoholic Fatty Liver Disease Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Non-Alcoholic Fatty Liver Disease Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Non-Alcoholic Fatty Liver Disease Market Landscape
6.1. Non-Alcoholic Fatty Liver Disease Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Non-Alcoholic Fatty Liver Disease Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
7.1.2. THR-β Agonists
7.1.3. GLP-1 Receptor Agonists
7.1.4. Antifibrotic Agents
7.1.5. FXR Agonists
7.1.6. Lipid-Lowering Agents
7.1.7. Thiazolidinediones
7.1.8. Antioxidants
7.1.9. Others
8. Non-Alcoholic Fatty Liver Disease Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
8.1.2. Parenteral
8.1.3. Oral
9. Non-Alcoholic Fatty Liver Disease Market – By Distribution
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
9.1.2. Retail Pharmacies
9.1.3. Hospital Pharmacies
9.1.4. Online Pharmacies
9.1.5. Others
10. Non-Alcoholic Fatty Liver Disease Market – By Age Group
10.1. Overview
10.1.1. Segment Share Analysis, By Age Group, 2025 & 2033 (%)
10.1.2. Geriatric
10.1.3. Adults
10.1.4. Pediatric
11. Non-Alcoholic Fatty Liver Disease Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Non-Alcoholic Fatty Liver Disease Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Madrigal Pharmaceuticals, Inc.
12.2.2. Novo Nordisk A/S
12.2.3. Eli Lilly and Company
12.2.4. F. Hoffmann-La Roche Ltd. / 89bio
12.2.5. Gilead Sciences, Inc.
12.2.6. AbbVie Inc.
12.2.7. Pfizer Inc.
12.2.8. Boehringer Ingelheim International GmbH
12.2.9. Inventiva S.A.
12.2.10. AstraZeneca plc
12.2.11. GSK plc
12.2.12. Viking Therapeutics, Inc.
12.2.13. Altimmune, Inc.
12.2.14. Sagimet Biosciences Inc.
12.2.15. Terns Pharmaceuticals, Inc.
12.2.16. Galectin Therapeutics Inc.
12.2.17. Galmed Pharmaceuticals Ltd.
12.2.18. NGM Biopharmaceuticals, Inc.
12.2.19. Bristol Myers Squibb
12.2.20. Zydus Lifesciences Ltd.
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Madrigal Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company
- Hoffmann-La Roche Ltd. / 89bio
- Gilead Sciences, Inc.
- AbbVie Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Inventiva S.A.
- AstraZeneca plc
- GSK plc
- Viking Therapeutics, Inc.
- Altimmune, Inc.
- Sagimet Biosciences Inc.
- Terns Pharmaceuticals, Inc.
- Galectin Therapeutics Inc.
- Galmed Pharmaceuticals Ltd.
- NGM Biopharmaceuticals, Inc.
- Bristol Myers Squibb
- Zydus Lifesciences Ltd.
- Others
GLOBALNON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- THR-β Agonists
- GLP-1 Receptor Agonists
- Antifibrotic Agents
- FXR Agonists
- Lipid-Lowering Agents
- Thiazolidinediones
- Antioxidants
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Parenteral
- Oral
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033
- Geriatric
- Adults
- Pediatric
GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
